Huang P, Chen S, Yang X, Lei Y Y, Xu X Y, Liu Y X, Guo Y H, Pan Y, Wang X H, Zhang H L, Fu K, Meng B
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin 300060, China; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China.
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):589-593. doi: 10.3760/cma.j.issn.0253-2727.2019.07.010.
To investigate the strong expression (S+) of P53 and BCL2 proteins in MYC/BCL2 double-expression DLBCL (DEL) and whether they can be used for the prognostic evaluation and stratified diagnosis of DELs. Tissue microarray were made by filed FFPE blocks of 174 DLBCL cases. The translocation of MYC, BCL2 and BCL6 genes were detected by FISH, and the proteins were detected by IHC. Data of clinicopathologic features and follow up of patients were collected and OS (overall survival) and PFS (progression free survival) were analyzed by statistics. Eight double-hit lymphomas (DHLs) were identified in all cases, and 45 DELs were selected from 166 remaining cases, which have no significant difference in OS and PFS compared with non-DEL cases (=0.668 and =0.790) . Of 42 DEL-cases with follow up data, 24 cases with P53+ or/and BCL2 (S+) are significantly shorter OS and PFS than others (=0.003 and =0.000) , in which the cases with P53+/BCL2 (S+) co-expression were the worst prognosis, and P53/BCL2 co-weaker positive DEL cases even have superior OS and PFS than those non-DELs. Although statistics showed that the cases of P53+ or/and BCL2 (S+) have a lower OS and PFS in total cases (=0.063 and =0.024) , it is not the case when the DEL-cases take out from total cases, that is the cases with P53+ or/and BCL2 (S+) are as similar OS and PFS as others in non-DEL group (=0.590 and =0.550) . The strong expression of P53 and BCL2 proteins can be used as indicators of stratified diagnosis and poor prognosis of DEL.
研究P53和BCL2蛋白在MYC/BCL2双表达弥漫性大B细胞淋巴瘤（DEL）中的强表达（S+）情况，以及它们是否可用于DEL的预后评估和分层诊断。用174例弥漫性大B细胞淋巴瘤病例的存档福尔马林固定石蜡包埋（FFPE）组织块制作组织芯片。采用荧光原位杂交（FISH）检测MYC、BCL2和BCL6基因的易位情况，采用免疫组化（IHC）检测蛋白表达情况。收集患者的临床病理特征及随访数据，并对总生存期（OS）和无进展生存期（PFS）进行统计学分析。所有病例中共鉴定出8例双打击淋巴瘤（DHL），从其余166例病例中选取45例DEL，其OS和PFS与非DEL病例相比无显著差异（P=0.668和P=0.790）。在42例有随访数据的DEL病例中，24例P53+或/和BCL2（S+）的病例OS和PFS明显短于其他病例（P=0.003和P=0.000），其中P53+/BCL2（S+）共表达的病例预后最差，而P53/BCL2共弱阳性的DEL病例的OS和PFS甚至优于非DEL病例。虽然统计学显示P53+或/和BCL2（S+）的病例在所有病例中的OS和PFS较低（P=0.063和P=0.024），但当从所有病例中剔除DEL病例时情况并非如此，即在非DEL组中，P53+或/和BCL2（S+）的病例与其他病例的OS和PFS相似（P=0.590和P=0.550）。P53和BCL2蛋白的强表达可作为DEL分层诊断和预后不良的指标。
